Rosuvastatin was equally effective in preventing a first cardiovascular event across categories of hsTnI ( aHR range , 0.50-0 .60 ) and BNP ( aHR range , 0.42-0 .67 ) with no statistically significant evidence of interaction ( P for interaction = 0.53 and 0.20 , respectively ) .